Becker's Healthcare May 16, 2024
Weight loss drugs have the potential to bankrupt the U.S. healthcare system, according to a May 15 report from Sen. Bernie Sanders’s office.
Mr. Sanders chairs the Senate Committee on Health, Education, Labor, and Pensions, which opened an investigation into Novo Nordisk’s list prices for Ozempic and Wegovy in April.
“It’s easy to oversimplify the science that goes into understanding disease and developing and producing new treatments, as well as the intricacies of U.S. and global healthcare systems,” a Novo Nordisk spokesperson told Becker’s at the time. “However, the public debate doesn’t always take into account this extremely complex reality.”
Medicare is barred from covering GLP-1s for weight loss only. In March, the FDA approved Wegovy for obese and overweight...
Today's Sponsors
Today's Sponsor